NCI issues grant for radio-immuno-guided surgery agent development

Editorial Staff | | Health Imaging | Molecular Imaging

Navidea Biopharmaceuticals, a biopharmaceutical company focused on diagnostic radiopharmaceuticals, has received a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), National Institutes of Health, to fund the development of its radio-immuno-guided surgery (RIGS) monoclonal antibody targeting agent for use in detecting metastatic sites in colorectal cancer.

The SBIR grant has the potential for grant money up to a total of $1.5 million over three years if fully funded, according to Navidea. The first-year Phase I funding of $315,000, which has already been approved, is expected to enable the Dublin, Ohio-based company to complete preclinical bridging activities using a RIGS tumor-antigen-targeted monoclonal antibody and prepare a standardization clinical trial protocol. Second and third year (Phase II) funding of up to $1.2 million is contingent upon meeting certain Phase I success criteria, including Institutional Review Board approval of the clinical trial protocol.

Editorial Staff

Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.